John P Brancaccio - Net Worth and Insider Trading
John P Brancaccio Net Worth
The estimated net worth of John P Brancaccio is at least $48,896 dollars as of 2024-11-29. John P Brancaccio is the Director of Cardiff Oncology Inc and owns about 12,260 shares of Cardiff Oncology Inc (CRDF) stock worth over $31,140. John P Brancaccio is the Director of OKYO Pharma Ltd and owns about 16,670 shares of OKYO Pharma Ltd (OKYO) stock worth over $17,337. John P Brancaccio is also the Director of Hepion Pharmaceuticals Inc and owns about 350 shares of Hepion Pharmaceuticals Inc (HEPA) stock worth over $224. Besides these, John P Brancaccio also holds Synergy Pharmaceuticals Inc (SGYPQ) . Details can be seen in John P Brancaccio's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John P Brancaccio has not made any transactions after 2023-09-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John P Brancaccio
John P Brancaccio Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John P Brancaccio owns 4 companies in total, including Hepion Pharmaceuticals Inc (HEPA) , Cardiff Oncology Inc (CRDF) , and Synergy Pharmaceuticals Inc (SGYPQ) among others .
Click here to see the complete history of John P Brancaccio’s form 4 insider trades.
Insider Ownership Summary of John P Brancaccio
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| HEPA | Hepion Pharmaceuticals Inc | 2020-12-02 | director |
| CRDF | Cardiff Oncology Inc | 2021-03-22 | director |
| SGYPQ | Synergy Pharmaceuticals Inc | 2018-07-04 | director |
 | | 2023-09-15 | director |
John P Brancaccio Latest Holdings Summary
John P Brancaccio currently owns a total of 4 stocks. Among these stocks, John P Brancaccio owns 12,260 shares of Cardiff Oncology Inc (CRDF) as of March 22, 2021, with a value of $31,140 and a weighting of 63.69%. John P Brancaccio owns 16,670 shares of OKYO Pharma Ltd (OKYO) as of September 15, 2023, with a value of $17,337 and a weighting of 35.46%. John P Brancaccio also owns 350 shares of Hepion Pharmaceuticals Inc (HEPA) as of December 2, 2020, with a value of $224 and a weighting of 0.46%. The other 1 stocks Synergy Pharmaceuticals Inc (SGYPQ) have a combined weighting of 0.4% among all his current holdings.
Latest Holdings of John P Brancaccio
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CRDF | Cardiff Oncology Inc | 2021-03-22 | 12,260 | 2.54 | 31,140 |
| OKYO | OKYO Pharma Ltd | 2023-09-15 | 16,670 | 1.04 | 17,337 |
| HEPA | Hepion Pharmaceuticals Inc | 2020-12-02 | 350 | 0.64 | 224 |
| SGYPQ | Synergy Pharmaceuticals Inc | 2017-05-26 | 30,444 | 0.01 | 195 |
Holding Weightings of John P Brancaccio
John P Brancaccio Form 4 Trading Tracker
According to the SEC Form 4 filings, John P Brancaccio has made a total of 2 transactions in Cardiff Oncology Inc (CRDF) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Cardiff Oncology Inc is the acquisition of 3,000 shares on March 22, 2021, which cost John P Brancaccio around $32,850.
According to the SEC Form 4 filings, John P Brancaccio has made a total of 1 transactions in OKYO Pharma Ltd (OKYO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in OKYO Pharma Ltd is the acquisition of 16,670 shares on September 15, 2023, which cost John P Brancaccio around $25,005.
According to the SEC Form 4 filings, John P Brancaccio has made a total of 1 transactions in Hepion Pharmaceuticals Inc (HEPA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Hepion Pharmaceuticals Inc is the acquisition of 350 shares on December 2, 2020, which cost John P Brancaccio around $10,710.
More details on John P Brancaccio's insider transactions can be found in the Insider Trading History of John P Brancaccio table.Insider Trading History of John P Brancaccio
- 1
John P Brancaccio Trading Performance
GuruFocus tracks the stock performance after each of John P Brancaccio's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John P Brancaccio is 37.35%. GuruFocus also compares John P Brancaccio's trading performance to market benchmark return within the same time period. The performance of stocks bought by John P Brancaccio within 3 months outperforms 2 times out of 7 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John P Brancaccio's insider trading performs compared to the benchmark.
Performance of John P Brancaccio
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 11.16 | | | | | |
| Relative Return to S&P 500(%) | 9.62 | | | | | |
John P Brancaccio Ownership Network
John P Brancaccio Owned Company Details
What does Hepion Pharmaceuticals Inc do?
Who are the key executives at Hepion Pharmaceuticals Inc?
John P Brancaccio is the director of Hepion Pharmaceuticals Inc. Other key executives at Hepion Pharmaceuticals Inc include Chief Scientific Officer Robert T Foster , Chief Financial Officer John T Cavan , and director & CEO and President Gary S Jacob .
Hepion Pharmaceuticals Inc (HEPA) Insider Trades Summary
Over the past 18 months, John P Brancaccio made no insider transaction in Hepion Pharmaceuticals Inc (HEPA). Other recent insider transactions involving Hepion Pharmaceuticals Inc (HEPA) include a net purchase of 8,000 shares made by Peter Wijngaard , and a net purchase of 3,200 shares made by Robert T Foster .
In summary, during the past 3 months, insiders sold 0 shares of Hepion Pharmaceuticals Inc (HEPA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Hepion Pharmaceuticals Inc (HEPA) were sold and 11,200 shares were bought by its insiders, resulting in a net purchase of 11,200 shares.
Hepion Pharmaceuticals Inc (HEPA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Hepion Pharmaceuticals Inc Insider Transactions
John P Brancaccio Mailing Address
Above is the net worth, insider trading, and ownership report for John P Brancaccio. You might contact John P Brancaccio via mailing address: C/o Tamir Biotechnology, Inc., 11 Deer Park Drive, Suite 204, Monmouth Junction Nj 08852.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
